ReviewNational science review2022
Natural products and drug discovery.
Review in National science review, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 2 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Global research landscape and multisystem health mechanisms of luteolin: a comprehensive bibliometric and network pharmacology study.Frontiers in nutrition · 2026Pooled it
- Pooled it
- A 'three-axis synergy' immunotherapeutic strategy for malignant bone tumors based on natural bioactives and bioactive materials.Bioactive materials · 2026Review
- Artificial Intelligence-Powered High-Content Analysis: Methodologies and Applications in Bioactive Compound Discovery from Natural Sources.Molecules (Basel, Switzerland) · 2026Review
- Inter-species horizontal transfer of biosynthetic gene clusters: an evolutionary driver for chemical diversity in bacterial communities.Essays in biochemistry · 2026Review
- Exploring the Chemical Space Around Protoflavonoids: Synthesis and Antitumor Activity of Protochalcones.ChemMedChem · 2026Article
- Phytochemical Characterization of Echeveria "Blue Curls" and Its Association With Redox-Metabolic Perturbations in Melanoma Cells.Chemistry & biodiversity · 2026Article
- Luteoagmacins A and B, new antimicrobial agmatine derivatives from a hot spring water-derived Luteococcus sp.The Journal of antibiotics · 2026Article
- Vasicine-Based Synergistic Antifungal Agents against FLC-ResistantACS medicinal chemistry letters · 2026Article
- Nudiloid Z, a New Labdane-Type Diterpenoid From Callicarpa nudiflora With Anti-Inflammatory Activity.Chemistry & biodiversity · 2026Article
- Penicophenone F from an Arctic Fungus Against UVB-Induced Corneal Damage via Inhibiting the ROS-EphA2 Pathway.Antioxidants (Basel, Switzerland) · 2026Article
- Metabolite diversification via halogen salts enhances biocontrol potential of marine-derived Trichoderma virens B211.Natural products and bioprospecting · 2026Article
- Notch signaling-targeted biomimetic hydrogel constructs an anti-inflammatory "flood-control" system to alleviate pyroptosis for intervertebral disc degeneration treatment.Materials today. Bio · 2026Article
- Antibacterial and Anticancer Potential ofInternational journal of molecular sciences · 2026Article
- Discovery of natural products that modulate signaling in patient-derived cells.RSC chemical biology · 2026Article
- Synthesis and Biological Evaluation of Curvularin-Type Derivatives with Potential Anti-Inflammatory, Anticancer, and Antimicrobial Activities.Molecules (Basel, Switzerland) · 2026Article
- Special Issue "Anticancer Drug Discovery Based on Natural Products".International journal of molecular sciences · 2026Article
- Trash or treasure? Unlocking dark matter of enantiomeric natural products in innovative drugs discovery for potent angiogenesis inhibitors.Marine life science & technology · 2026Article
- Design and Synthesis of Marine Sarocladione Derivatives with Potential Anticancer Activity.Marine drugs · 2026Article
- A Simple and Versatile Cell-Free Expression Method for Producing Secondary Metabolites.ACS synthetic biology · 2026Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review covers the recent history of a series of very important natural products and their derivatives that are currently in use or under evaluation in the areas of anti-infectives, important cancer treatments that include antibody drug conjugates, followed by a discussion of type 2 diabetes (T2DM) drugs and angiotensin converting enzyme inhibitors. The current structures of the agents are shown, though in the case of some peptides used in T2DM drugs the standard single letter abbreviation for an amino acid is used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.